The global allergic diesae is likely to increase incidence and complications,
Conditions
Interventions
continue HDM SCIT maintenance protocol ,switch from HDM SCIT to HDM SLIT in maintenance phase
Active Comparator Drug,Experimental Drug
continue HDM SCIT ,HDM SLIT
Sponsors
Department of medicine, Phramongkutklao hospital
Allergy and clinical immunology mediciine department,
Phramongkutklao hospital ,abbott laboratories
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Age of 18-65 years 2. diagnosed allergic rhinitis and/or asthma 3. In asthma patient; FEV1 more than 70% predicted 4. skin prick test or specific IgE positive to Der p or Der f 5. on going SCIT in maintenance phase during 2 month to 3 years
Exclusion criteria
Exclusion criteria: 1.history of allergic to SLIT 2. uncontrolled asthma within 3 months 3. Autoimmune disease 4. active upper respiratory tract infection 5. psychiatric disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical efficacy of HDM SLIT and SCIT in maintenance phase 3 months total nasal symptoms score, Total medication score, asthma control test score | — |
Secondary
| Measure | Time frame |
|---|---|
| Laboratories about the efficacy of HDM SLIT and SCIT in maintenance phase 3 months regulartory T cell | — |
Countries
Thailand
Contacts
Public Contactploykarn kiatiwat
023544106
Outcome results
None listed